Summary & Overview
CPT 17276: Destruction of Malignant Cutaneous Lesion >4.0 cm
CPT code 17276 captures the destruction of a malignant cutaneous lesion greater than 4.0 cm in diameter on anatomically sensitive locations including the scalp, neck, hands, feet, or genitalia. As a procedure-level dermatologic code, it defines scope of service and supports claims for non-excisional destructive treatment using chemosurgery, cryosurgery, electrosurgery, or other destructive modalities. Nationally, accurate use of this code affects reimbursement, quality measurement, and coding consistency for high-acuity skin cancer management performed in outpatient and ambulatory surgical settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with benchmarks on coding and utilization patterns, clarifies clinical context for when destruction (rather than excision) is reported, and summarizes relevant policy considerations and recent payer instructions where available. Readers will find concise guidance on expected sites of service, common clinical scenarios covered by this code, and an overview of documentation elements typically associated with billing for large-diameter malignant lesion destruction. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 17276 describes the destruction of a malignant lesion greater than 4.0 cm in diameter using techniques such as chemosurgery, cryosurgery, electrosurgery, or other destructive methods. The procedure addresses malignant lesions located on the scalp, neck, hands, feet, or genitalia.
Service type: Destruction of malignant cutaneous lesion (surgical/dermatologic procedure)
Typical site of service: Outpatient surgical suite, dermatology clinic, or ambulatory procedure center
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old fair-skinned male with a history of sun exposure who presents to a dermatology clinic with a large, irregular, ulcerating lesion on the scalp measuring 4.5 cm in greatest diameter. Biopsy demonstrates invasive squamous cell carcinoma. The procedural plan is in-clinic destruction of the malignant lesion using electrosurgery with local anesthesia because the lesion is superficial, the patient prefers a non-excisional approach, and surgical resection with grafting is not indicated or feasible.
The clinical workflow includes: referral and biopsy confirmation of malignancy, pre-procedure informed consent and review of medical history and anticoagulation, pre-procedural lesion mapping and measurement, administration of local anesthesia, lesion destruction using electrosurgical/chemosurgical/cryosurgical technique, hemostasis and wound care instructions, documentation of lesion size (>4.0 cm), and post-procedure follow-up for wound healing and oncologic surveillance. Typical site of service is an outpatient dermatology clinic or ambulatory surgical center; service type is office-based ambulatory procedure for destruction of a malignant lesion larger than 4.0 cm on scalp/neck/hands/feet/genitalia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office/outpatient E/M service | When an unrelated E/M visit is separately reported on the same day as the procedure and the provider performs the visit services. |